Calderasib

Calderasib (MK-1084) is a small-molecule drug developed by Merck Sharp & Dohme. Its target is KRAS (the sponsor names KRAS G12C). The sponsor states: MK-1084 is described as an investigational, oral, selective KRAS G12C inhibitor. It is the investigational product in 6 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07554339 (A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)), NCT06345729 (A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumour Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)) and NCT07431827 (MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)), in non-small-cell lung cancer and colorectal cancer. The largest, NCT07190248, plans to enrol 675 participants with primary completion expected 2029-12-07. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.